SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
Topline results using the Company's SCI-110 met the trial’s primary and secondary end points, demonstrating high safety profile and reduced agitationTel-Aviv, June 02, 2023 -- SciSparc Ltd. ,... | June 2, 2023
Source: marketscreener.com